Blog

Nelson Advisors featured in InnLifes article 'Come è nata Wise: la medtech italiana che rivoluziona il neuromonitoraggio e la neuromodulazione con elettrodi impiantabili ergonomici'Translated as 'How Wise was founded: the Italian medtech company revolutionizing neuromonitoring and neuromodulation with ergonomic implantable electrodes.'Source: <a href="https://www.innlifes.com/med-tech/la-storia-di-wise-elettrodi-per-cervello/" data-mce-href="https://www.innlifes.com/med-tech/la-storia-di-wise-elettrodi-per-cervello/">https://www.innlifes.com/med-tech/la-storia-di-wise-elettrodi-per-cervello/</a>«Siamo manifatturieri e rimarremo manifatturieri», dice Ravagnan. Wise Cortical Strip, il prodotto da cui tutto è cominciato, continua ad aprire possibilità prima impensabili per i neurochirurghi. Il salto di scala, però, arriverà da Heron e da ciò che verrà dopo. Intanto, Nelson Advisors, società di advisory finanziario con sede a Londra, annovera Wise tra le “20 Future Italian HealthTech and MedTech Leaders”."We are manufacturers, and we will remain manufacturers," says Ravagnan. The Wise Cortical Strip—the product that started it all—continues to open up possibilities for neurosurgeons that were previously unimaginable. However, the leap in scale will come from Heron and what follows it. Meanwhile, Nelson Advisors, a London-based financial advisory firm, has named Wise one of the "20 Future Italian HealthTech and MedTech Leaders."KEYPOINTSParola chiave: serendipità. Una scoperta nata per caso in laboratorio ha portato alla creazione di un materiale conduttivo, elastico e biocompatibile e alla nascita di Wise. La tecnologia proprietaria di Wise impianta nanoparticelle nel silicone per realizzare circuiti flessibili ad alta precisione. Dal confronto con i neurochirurghi del Besta di Milano è nato un elettrodo che migliora il monitoraggio cerebrale durante gli interventi. WISE Cortical Strip è oggi un dispositivo certificato in Europa, approvato negli Stati Uniti e già utilizzato nella pratica clinica. Con Heron invece Wise punta a rivoluzionare la terapia del dolore cronico con un elettrodo minimamente invasivo che si apre una volta impiantato. Wise ha chiuso un round da 30 milioni che investirà nello sviluppo di Heron, mantenendo ricerca e produzione a Cologno Monzese.

Nelson Advisors featured in InnLifes article 'Come è nata Wise: la medtech italiana che rivoluziona il neuromonitoraggio e la neuromodulazione con elettrodi impiantabili ergonomici'

The European HealthTech landscape is seeing a definitive, practical shift. The era of speculative consumer wellness apps has taken a backseat, replaced by a heavy focus on deep-tech clinical solutions, interoperability and reducing administrative burnout for healthcare staff.The major developments shaping European HealthTech include:1. Regulatory Shifts: Navigating the AI Act &amp; MDR OverlapStartups and mature HealthTech companies are currently grappling with dual compliance demands as the EU AI Act and the stringent Medical Device Regulations (MDR/IVDR) intersect.The Compliance Friction: Developers of AI-driven medical tech are facing parallel, overlapping regulatory requirements. Industry bodies are aggressively lobbying the European Commission to streamline these rules; the EU Parliament projects that cutting this administrative bloat could save the ecosystem up to €3.3 Billion annually.The UK’s "International Reliance" Play: Capitalising on mainland Europe's regulatory bottleneck, the UK’s MHRA has progressed its draft Medical Devices Regulations. This creates an "International Reliance" pathway, allowing manufacturers with approvals from trusted global regulators (like the US FDA) to fast-track their entrance into the UK market and bypass redundant testing. 2. Deep-Tech &amp; Interoperability FundingVenture capital and EU grants are favouring heavily vetted, clinical-grade innovations over lifestyle software.Smart Contact Lenses: Belgian healthtech firm Azalea Vision secured up to €7.5 million from the EU’s European Innovation Council (EIC) Accelerator program. The funding will advance their medical-grade smart contact lens, which treats complex vision issues and tracks biomarkers in tears—into clinical trials.Crushing Data Silos: The EIC announced the first winners of its health data interoperability initiative, deploying a combined €3.78 million to projects like CARDIO-HUB (remote heart monitoring for the elderly) and NEODATA+(neonatal intensive care data). The goal is a shift from isolated "pilot programs" to full-scale cross-border data deployment.AI Foundation Toxicology: A new Horizon Europe funding call via the Innovative Health Initiative (IHI) was introduced to back a collaborative consortium developing an AI Foundation Toxicology Model, aiming to use machine learning to safely consolidate pharmaceutical data and predict drug safety early on.3. Commercial Realities: From "Promise to Proof"Data from recent industry forums like HLTH Europe and the Philips Future Health Index highlight a major vibe shift among buyers:Workflow Automation is King: Roughly 65% of European clinicians have actively ramped up their use of AI medical tech, but primarily to claw back time from administrative duties.As a result, B2B software that tackles clinician burnout and optimizes hospital infrastructure (such as open, interoperable clinical platforms) is securing the lion's share of late-stage funding, while pure-play wellness apps are seeing a steep decline in institutional backing. The Emerging Risk: Legal experts warn that because formal "AI literacy" training requirements for doctors have been diluted in recent legislative drafts, manufacturers face a growing liability threat if a time-strapped clinician incorrectly interprets an AI diagnostic output.&gt;&gt;&gt;&gt;The European MedTech sector is undergoing an intense structural shift. While software-heavy HealthTech is moving toward workflow automation, physical medical hardware and devices (MedTech) are hitting massive regulatory and procurement bottlenecks, sparking significant updates and pushback this week.The defining MedTech developments shaping the European market include:1. Regulatory Overlap Crisis: The MDR vs. SoHO ClashThe single biggest headline in European medical hardware this week is a formal warning issued by a Council of Europe committee (the CD-P-TO).The Overlap: The committee warned that an "overly expansive" interpretation of the Medical Device Regulation (MDR) is directly threatening patient access to therapies based on human blood, tissues, and cells.The Conundrum: The new Substances of Human Origin (SoHO) legislation is set to fully apply by August 2027. Right now, manufacturers are panicking because they risk entering the post-2027 era simultaneously answerable to two distinct, overlapping regulatory regimes—complete with separate inspection frameworks and duplicate documentation.The Impact: Because low-volume, highly specialized medical devices are being withdrawn from the European market due to high MDR compliance costs, some health institutions are resorting to using "Research Use Only" (RUO) devices outside of their intended purposes just to maintain patient care. Industry groups are demanding immediate intervention from the European Commission to separate the two rules.2. In Vitro Diagnostics (IVD) Market AlarmFollowing the ongoing rollout of the In Vitro Diagnostics Regulation (IVDR), Europe's €13 billion IVD sector is sounding the alarm on a major supply chain bottleneck.The Problem: Paradoxically, while European Notified Bodies (the organizations that validate device safety) have recently cut staff due to a temporary slowdown in technical documentation submissions, the testing pipeline itself is incredibly fragile.The Pushback: MedTech Europe published an aggressive position paper welcoming some proposed EU revisions but demanding urgent tweaks to how the continent handles orphan diagnostics, risk classifications, and health institution tests. The sector warns that without a simplified, predictable, risk-based framework, European patients will lose access to critical lab diagnostics.3. Procurement Pivot: Recommending "Value Over Low Price"A major strategic shift is underway regarding how European hospitals purchase capital medical equipment and implantables.Ending Price-Only Tenders: Historically, European public healthcare systems have relied heavily on price-only procurement, which naturally favours cheaper imports and undercuts high-quality local hardware manufacturers.The New Framework: This week, industry leaders mobilized a massive push toward Value-Based Procurement.Citing frameworks co-developed with the Boston Consulting Group, trade bodies are pressuring EU member states to rewrite hospital bidding rules. The goal is to prioritize long-term clinical outcomes, risk-sharing agreements with suppliers, and supply chain resilience over the lowest sticker price. The Geopolitical Context: Midway through 2026, European hardware firms are facing severe macroeconomic headwinds compared to their US counterparts. Due to ongoing reciprocal trade tariffs on goods entering the US (Europe's primary export market), European MedTech manufacturers are leaning heavily on local EU grants—like the newly opened Innovative Health Initiative (IHI) Incubator Network calls—to fund early-stage hardware commercializationNelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb</a>&nbsp;Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTlloyd@nelsonadvisors.co.ukpaul@nelsonadvisors.co.ukMeet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

This Week in European MedTech and HealthTech: 10th July 2026

GeriCare wins UCL GBSH Dragons' Den 2026 with AI-powered support for dementia carers<a href="https://www.ucl.ac.uk/population-health-sciences/news/2026/jul/gericare-wins-ucl-gbsh-dragons-den-2026-ai-powered-support-dementia-carers" data-mce-href="https://www.ucl.ac.uk/population-health-sciences/news/2026/jul/gericare-wins-ucl-gbsh-dragons-den-2026-ai-powered-support-dementia-carers">https://www.ucl.ac.uk/population-health-sciences/news/2026/jul/gericare-wins-ucl-gbsh-dragons-den-2026-ai-powered-support-dementia-carers</a>The next generation of healthcare innovators took centre stage at the UCL Global Business School for Health (GBSH) Dragons’ Den 2026, presenting ambitious solutions to real-world healthcare challenges before an expert panel of entrepreneurs, investors and industry leaders.The annual competition provides students with an opportunity to demonstrate critical thinking, leadership and commercial awareness while addressing some of healthcare’s most pressing problems.This year’s event marked a significant milestone, welcoming undergraduate students into the competition for the first time and reinforcing GBSH’s commitment to fostering innovation across all levels of study.Following a competitive application process that attracted 16 submissions, six teams advanced to the final after participating in a series of preparation and pitch-development sessions. Finalists pitched their ideas in a live Dragons’ Den format, with five minutes to present and ten minutes to answer questions from the judging panel.The finalist teams were:EvluveWellFactsEquiNovaWaitWellGeriCarepHase PharmaThe Dragons included renowned cancer surgeon and health technology pioneer Professor Shafi Ahmed; healthtech entrepreneur and GBSH Health Executive in Residence Lloyd Price; Students’ Union UCL Engagement Assistant Nifemi Wilson-Adu; and founder of HUM2N, Dr Mohammed Enayat.

GeriCare wins UCL GBSH Dragons' Den 2026 with AI-powered support for dementia carers

Re-Engineering the UK HealthTech Market: Will NHS Reform Unlock Scale or Remain a Graveyard for Pilots? The United Kingdom’s HealthTech and MedTech sectors are navigating a structural transition. Following a multi-year period of post-pandemic valuation compression, capital scarcity, and constrained public market activity between 2023 and 2025, the market is demonstrating signs of strategic acceleration and operational evolution. &nbsp;The state is increasingly acting as a primary market-maker. The convergence of the National Health Service (NHS) 10 Year Health Plan, the Medicines and Healthcare products Regulatory Agency’s (MHRA) updated regulatory roadmap for Software as a Medical Device (SaMD), and the Treasury's Mansion House Reforms to mobilise domestic pension capital has created a policy architecture designed to de-risk commercial investment. &nbsp; However, the central question for venture capital, private equity, and institutional investors is whether this programmatic restructuring can dismantle the historical "pilotitis" that has plagued the NHS. While the shift toward Integrated Care Systems (ICSs) and centralised procurement frameworks theoretically establishes a scalable, single-buyer domestic market, significant frictions remain at the local level. Navigating the interface between national commercial mandates and the statutory independence of local Integrated Care Boards (ICBs) is now the primary determinant of whether the UK can transition from a fragmented collection of local pilots into a highly investable, globally competitive health market.Analytical Synthesis and Investability Outlook &nbsp;&nbsp; The programmatic reforms enacted across the UK health system in 2025 and 2026 are intended to make the UK an investable market again. However, an economic and structural analysis indicates that the domestic market is not a uniform landscape of opportunity, but a bifurcated system where capital must be selectively deployed. &nbsp;&nbsp; The "Bull Case" for UK investability is supported by the regulatory triple-lock of the NHS 10-Year Health Plan, the consolidated NICE HealthTech pathway (which brings mandated funding for validated digital products), and the mobilisation of domestic pension capital via the Mansion House reforms. By establishing the MedTech Compass and the Innovator Passport, the state is actively attempting to streamline the commercial pathway, allowing validated technologies to scale across the NHS without repeating costly, localised technical assessments. &nbsp;&nbsp; The "Bear Case," however, is sustained by the structural reality of the 42 independent ICSs. Because local ICBs retain statutory responsibility for their budgets, they possess de facto veto power over national procurement frameworks. Under severe workforce and short-term capital constraints, local commissioners routinely prioritise acute deficit reduction over long-term value-based technology procurement.&nbsp; &nbsp;&nbsp; Furthermore, the historical evaluation of large scale NHS IT investments demonstrates that socio technical barriers and legacy system integration often dilute the clinical impact of centralised procurement mandates. &nbsp;&nbsp; For professional investors and market operators, the UK healthcare market in 2026 is no longer a "growth-at-all-costs" environment, but a market defined by "profitable efficiency" and "clinical validation". Capital should be directed toward four strategic corridors: &nbsp;&nbsp; Administrative and Workflow Automation: SaaS solutions that automate back-office operations, billing, and clinical documentation (such as AVT and RCM) face fewer clinical behaviour-change barriers and demonstrate faster adoption rates than complex clinical decision-support tools.Clinically Mandated Day-Case Technologies: Innovations that align with the "Left Shift" by migrating complex procedures from high-cost inpatient theaters to community settings (such as minimally invasive devices validated under VBP or the MTFM) possess a strong commercial tailwind.Consolidated ICS Infrastructure: Private equity operators can capitalize on the fragmentation of the UK healthcare back-office by pursuing "buy-and-build" consolidation strategies of sub-£50 million clinical IT and data infrastructure providers.Risk-Sharing and Outcome-Based Contracting: To secure national-scale contracts, HealthTech firms must transition from transactional product sales to strategic partnerships where payment is linked to measurable improvements in staff efficiency, bed-day reductions, or clinical outcomes. &nbsp;&nbsp; Ultimately, the UK healthcare market has successfully transitioned its policy architecture from a fragmented "graveyard of pilots" toward a more unified, scalable domestic market. However, the practical realisation of this scalable market is not achieved through top-down mandates alone; it requires constant navigation of the socio technical, clinical and financial frictions that define the frontline of the NHS. Click here to read the report in full <a href="https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-will-nhs-reform-make-the-uk-investable-again" data-mce-href="https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-will-nhs-reform-make-the-uk-investable-again">https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-will-nhs-reform-make-the-uk-investable-again</a> &nbsp;Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; &nbsp;Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital" data-mce-href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb" data-mce-href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp;Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk" data-mce-href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 Events &nbsp; &nbsp;Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; &nbsp;Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; &nbsp;HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; &nbsp;Venture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors Big Questions in HealthTech Series: Will NHS reform make the UK investable again?

The financing of European medical technology is undergoing a structural transition that challenges the viability of its historical funding mechanisms. For decades, early-stage medtech innovation relied on the traditional venture capital model, which was originally pioneered to support the rapid scaling, high gross margins and predictable, capital-efficient exit pathways of the software industry.&nbsp; &nbsp; However, the combination of physical hardware development timelines, complex and localised national reimbursement frameworks, and the operational demands of the EU Medical Device Regulation (MDR) has exposed a fundamental mismatch between the investment horizon of venture capital and the development cycles of modern medical technologies. &nbsp; This mismatch is reflected in a severe contraction in growth-stage venture capital. While early-stage seed and Series A valuations have shown nominal resilience, the volume of capital available for subsequent rounds has collapsed. Total investment in growth-stage healthcare in late 2024 was 84% lower than its peak in late 2021, creating a severe supply-demand bottleneck as a surplus of Series A companies compete for a dwindling pool of follow-on growth capital. This venture funding gap is compounded by a dramatic decline in fundraising. Early-stage life sciences venture fundraising plummeted by over 80% from 2021 to 2022, and despite a partial rebound, it remains 46% below 2021 levels, meaning that the "dry powder" accumulated during the pandemic boom has been largely exhausted. At the same time, regulatory changes under the Capital Requirements Regulation (CRR) and Capital Requirements Directive (CRD) have raised the cost of bank investments in private equity and venture capital funds, further restricting the flow of institutional capital into high-risk asset classes. &nbsp;&nbsp; Consequently, the European medtech ecosystem has entered an era of "industrial maturity". This phase is characterised by a departure from the "growth at all costs" paradigm that defined the zero-interest-rate policy (ZIRP) era. Valuation metrics have shifted from speculative user-acquisition numbers to strict fundamentals, clinical validation, unit economics, and risk-mitigated regulatory positioning. To maintain global competitiveness, European medtech must evaluate alternative capital formation strategies.ConclusionVenture capital is a mismatched financial instrument when applied as a single source of capital across the entire medtech development lifecycle. The structural friction of the EU MDR, combined with localised reimbursement fragmentation and incompressible clinical timelines, has broken the traditional venture capital "escalator" in Europe.&nbsp; &nbsp; However, the proposal to fund medtech from "day one" utilising debt or royalties is a structural impossibility due to the underwriting standards of these credit and yield-based instruments. &nbsp;&nbsp; The solution for European medtech is the construction of a diversified capital stack. Founders must sequence public non-dilutive grants and tax incentives to fund early-stage R&amp;D; transition to patient, evergreen family offices and strategic corporate venture capital to navigate clinical validation and regulatory review; and unlock venture debt, private credit and synthetic capped royalties only after securing regulatory clearance and establishing commercial revenue visibility.&nbsp; &nbsp;&nbsp; By re-engineering the capital stack to match capital structures with underlying asset risk, European medtech can bypass the growth equity bottleneck, preserve founder equity, and bring clinical innovations to patients globally.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-is-venture-capital-right-for-medtech-should-mor">https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-is-venture-capital-right-for-medtech-should-mor</a>Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a> Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp;&nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 Events &nbsp; Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; Venture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors Big Questions in HealthTech Series: Is Venture Capital right for MedTech? Should more European MedTech be funded by debt, royalties or strategics from day one?

Moat or Millstone: Layered AI Regulation, Transatlantic Arbitrage and the Geopolitics of Frontier Innovation The global landscape of artificial intelligence governance has crystallised into three distinct philosophical paradigms: the Rights-Based approach championed by the European Union, the Innovation-First model pursued by the Gulf Cooperation Council (GCC) and Singapore, and the State-Directed framework enforced by China. Within this geopolitical matrix, the European Union’s Artificial Intelligence Act (AI Act), which entered into force on August 1st, 2024, serves as the world's first comprehensive horizontal legislative framework for AI. Yet, as its implementation phases activate, a critical debate has emerged: is this framework a stabilising regulatory moat that guarantees safety and transparency, or is it a compliance millstone that stifles early-stage innovation and drives top-tier technical founders out of the bloc? This tension is most acute in highly regulated sectors such as digital health and medical technology (MedTech). Here, developers face a compounding "double lock": the sector-specific demands of the Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR) paired with the horizontal, systemic risk-mitigation layers of the AI Act. This analysis evaluates the economic, operational, and structural implications of this layered regulatory environment, contrasting Europe's precautionary posture with the aggressive deregulation of the United States and the infrastructure-led, capital-rich incentives of the Gulf.Conclusion: The Asymmetric Moat and Strategic Workarounds The question of whether the EU AI Act represents a protective moat or a compliance millstone is resolved by the size and capitalisation of the organisation in question. For well-capitalised incumbents, the layered regulatory stack of the MDR, IVDR, and AI Act functions as a powerful, defensible moat. By compounding existing certifications, clinical trial registries, and exclusive partnerships with clinical data networks under the EHDS, large players can establish first-mover advantages that are difficult for new entrants to challenge. For early-stage, AI-native startups, however, this regulatory environment is an administrative and financial millstone. The high upfront costs of QMS integration, long delays in Notified Body audits, and a lack of local computing power create barriers that can drain startup resources. Consequently, a clear strategic divergence has emerged: By sequencing their development across multiple markets, next-generation founders do not have to abandon the European market. Instead, they can treat the US and the Gulf as engines for rapid product scaling and cash-flow generation, returning to Europe only when they possess the financial runway and institutional backing to transform its complex regulations into their own defensive moat. Click here to read the report in full <a href="https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-is-the-eu-ai-act-a-moat-or-a-millstone" data-mce-href="https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-is-the-eu-ai-act-a-moat-or-a-millstone">https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-is-the-eu-ai-act-a-moat-or-a-millstone</a>Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital" data-mce-href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb" data-mce-href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp; Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp;&nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk" data-mce-href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>&nbsp;&nbsp; Meet Nelson Advisors @ 2026 Events &nbsp; Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; Venture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors

Blog

Nelson Advisors featured in InnLifes article 'Come è nata...

This Week in European MedTech and HealthTech: 10th July 2026

GeriCare wins UCL GBSH Dragons' Den 2026 with AI-powered ...

Nelson Advisors Big Questions in HealthTech Series: Will ...

Nelson Advisors Big Questions in HealthTech Series: Is Ve...

Nelson Advisors Big Questions in HealthTech Series: Is th...